Patents by Inventor Joseph Senn

Joseph Senn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220265857
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    Type: Application
    Filed: January 25, 2022
    Publication date: August 25, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
  • Publication number: 20220125899
    Abstract: The present application is related to a method of treating a cancer by administering to a human subject multiple doses of a mRNA cancer vaccine formulated as a lipid nanoparticle wherein the cancer vaccine comprises one or more mRNAs each having one or more open reading frames encoding 3-50 peptide epitopes, and wherein each of the peptide epitopes are portions of personalized cancer antigens or portions of cancer hotspot antigens. The present application further relates to a method of treating cancer by combining anti-cancer immunotherapy with the administration of the aforementioned mRNA cancer vaccine.
    Type: Application
    Filed: November 7, 2019
    Publication date: April 28, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Ted Ashburn, Kristen Hopson, Karen Keating, Joseph Senn, Christine Swenson, Benjamin Breton, Shan Zhong, Maija Garnaas
  • Patent number: 11285222
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: March 29, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
  • Patent number: 10962330
    Abstract: A device and method for aligning a sighting device with a reference. The device includes features conforming to an industry standard for attaching accessories to a firearm. The device contains features which allow the device to be leveled relative to a removable level. A sighting device may be attached to the device using the industry standard features. Once attached, the sighting device may then be aligned using either the removable level or an external reference. Once the sighting device is secured in its mount, the mounted sight may then be installed and removed from one or more devices without its calibrated orientation being altered.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: March 30, 2021
    Assignee: Inventure Engineering and Machine, LLC
    Inventor: Anthony Joseph Senn
  • Publication number: 20200206362
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    Type: Application
    Filed: October 11, 2019
    Publication date: July 2, 2020
    Applicant: Moderna TX, Inc.
    Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
  • Patent number: 10556018
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: February 11, 2020
    Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
  • Patent number: 10485885
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: November 26, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
  • Publication number: 20190117798
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 25, 2019
    Applicant: ModernaTX, Inc.
    Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
  • Patent number: 10207010
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: February 19, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
  • Publication number: 20180328696
    Abstract: A device and method for aligning a sighting device with a reference. The device includes features conforming to an industry standard for attaching accessories to a firearm. The device contains features which allow the device to be leveled relative to a removable level. A sighting device may be attached to the device using the industry standard features. Once attached, the sighting device may then be aligned using either the removable level or an external reference. Once the sighting device is secured in its mount, the mounted sight may then be installed and removed from one or more devices without its calibrated orientation being altered.
    Type: Application
    Filed: May 10, 2018
    Publication date: November 15, 2018
    Applicant: INVENTURE ENGINEERING AND MACHINE, LLC
    Inventor: Anthony Joseph Senn
  • Publication number: 20180147298
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    Type: Application
    Filed: August 10, 2017
    Publication date: May 31, 2018
    Applicant: ModernaTX, Inc.
    Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
  • Publication number: 20180028664
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    Type: Application
    Filed: August 11, 2017
    Publication date: February 1, 2018
    Applicant: ModernaTX, Inc.
    Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
  • Patent number: 8568976
    Abstract: The present invention provides compositions and methods for identifying and utilizing proinflammatory nucleic acids. In particular, this invention relates to compounds, particularly oligonucleotides, which exert their effect through triggering receptors expressed by myeloid cells (TREMs), specifically TREM 2.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: October 29, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Joseph Senn
  • Publication number: 20120295272
    Abstract: The present invention provides compositions and methods for identifying and utilizing proinflammatory nucleic acids. In particular, this invention relates to compounds, particularly oligonucleotides, which exert their effect through triggering receptors expressed by myeloid cells (TREMs), specifically TREM 2.
    Type: Application
    Filed: December 12, 2011
    Publication date: November 22, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Joseph Senn
  • Patent number: 8101345
    Abstract: The present invention provides compositions and methods for identifying and utilizing proinflammatory nucleic acids. In particular, this invention relates to compounds, particularly oligonucleotides, which exert their effect through triggering receptors expressed by myeloid cells (TREMs), specifically TREM 2.
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: January 24, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Joseph Senn